http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-354034-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e5edd48190cba3fa70dd3975efd9831
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
filingDate 1968-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 1970-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber ES-354034-A1
titleOfInvention PROCEDURE FOR OBTAINING NEW PIRIDIL-TETRAHI- DROISOQUINOLEINS.
abstract Novel compounds of Formula I in which the pyridine radical is linked in the 3- or 4-position with the tetrahydroisoquinoline ring R 2 is C 1-5 alkyl R 1 is C 1-5 alkyl, or a benzyl radical optionally substituted by a methyl group R 3 is a hydrogen atom, C 1-2 alkyl or a halogen atom R 4 and R 5 are hydrogen atoms or C 1-2 alkyl and R 6 is a hydrogen atom, C 1-3 alkyl or C 1-3 aliphatic acyl and their physiologically acceptable acid addition salts are prepared (a) when R 6 is H by reduction of the corresponding dihydroisoquinoline (b) when R 6 is a formyl or methyl group by reduction of the corresponding dihydroisoquinoline with simultaneous introduction of a formyl or methyl group at the isoquinoline ring nitrogen atom (c) when R 6 is H by cyclization of amines of formula R 3 .C 6 H 4 .CH(R 5 ).C(R 1 )R 2 .NH 2 with the appropriate pyridine-3- or -4-aldehyde with liberation of water (d) when R 6 is a C 1-3 acyl group by reaction of the corresponding carboxylic acid anhydride or halide with the corresponding 2-H isoquinoline derivative (e) when R 6 is C 1-3 alkyl by reduction of the corresponding C 1-3 acyl group in a compound of Formula I, where R 6 is acyl (f) when R 6 is methyl by reaction of the corresponding isoquinoline in which R 6 is H with paraformaldehyde and formic acid or with formaldehyde and catalytically activated hydrogen or (g) when R 6 is C 1-3 alkyl and R 4 is H by reacting a corresponding 3,4-dihydroisoquinolinium salt with an organometallic pyridyl compound C 5 NH 4 X, where X is a halomagnesium radical or lithium atom in the 3- or 4-position. Intermediates isolated are 4-pyridylmethylidene- (1,1 - dimethyl - 2 - phenyl) - ethylamine from pyridine - 4 - aldehyde and 1 - phenyl - 2 - methyl - 2 - propylamine 3 - pyridylmethylidene - (1,1 - dimethyl - 2 - phenyl) - ethylamine 4 - pyridylmethylidene - (1 - ethyl - 1 - methyl - 2- phenyl) - ethylamine 4 - pyridylmethylidene- [1,1 - dimethyl - 2 (p - methylphenyl)] - ethylamine and 4 - pyridylmethylidene - (1,1,2 - trimethyl-2-phenyl)-ethylamine. Pharmaceutical compositions comprise compounds of Formula I or pharmaceutically acceptable acid addition salts thereof in conjunction with suitable carriers and/or diluents, are administered orally, rectally or parenterally and possess antiphlogistic, antipyretic, analgesic and spasmolytic activity.
priorityDate 1966-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1140
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394721
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID284
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13389
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID712
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID422511
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407631466
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1049
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8405
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425901710
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4738526
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4210355
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419765309
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392901
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456485498
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419547992
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415962841
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559587
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3028194
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426023247
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420319568
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407559142
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414515617
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID420312335
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458392451

Total number of triples: 38.